Ensysce Biosciences, Inc. ENSC
were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from
PharmacoFore, Inc. to Signature Therapeutics Inc. ("Signature"). In December 2015, Signature merged with and into
Ensysce Biosciences, Inc. ("Former Ensysce"). In June 2021, Former Ensysce merged with and into Leisure Acquisition
Corporation ("LACQ"). As part of the transaction, LACQ changed its name to "Ensysce Biosciences, Inc."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M | — | — | — |
| R&D | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M | $4.4M | — | — | — |
| SG&A | $4.9M | $4.7M | $5.4M | $6.9M | $18.7M | $1.2M | — | — | — |
| Total operating expenses | $15.3M | $11.9M | $12.9M | $26.7M | $23.4M | $5.5M | $3.3M | $1.6M | — |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M | -$1.6M | -$3.3M | -$959.2K | — |
| Interest expense | $18.8K | $1.3M | $353.9K | $109.5K | $1.3M | $995.5K | — | — | — |
| Pre-tax income | — | — | — | — | — | $4.6M | -$512.1K | $2.7M | — |
| Income tax | — | — | — | — | — | $244.5K | $555.2K | $553.9K | — |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$24.2M | -$29.1M | -$160.9K | -$1.1M | $2.1M | — |
| EPS, basic | -3.98 | -11.45 | -70.40 | -139.42 | -29.64 | 0.00 | — | — | — |
| EPS, diluted | -3.98 | -11.45 | -70.40 | -139.42 | -1.48 | 0.00 | -0.63 | -0.21 | — |
| Shares, diluted (wtd. avg.) | 2.6M | 697,686 | 150,937 | 179,925 | 1.0M | 16.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M | $194.2K | — | — | — |
| Total current assets | $7.2M | $5.3M | $2.3M | $5.3M | $15.7M | $347.9K | $1.2M | $1.9M | $2.3M |
| Property, plant and equipment | $124.1K | — | — | — | — | $151 | — | — | — |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M | $351.8K | $196.5M | $204.8M | $202.4M |
| Accounts payable | $3.3M | $1.4M | $1.9M | $2.9M | $301.1K | $1.7M | $2.8M | $429.2K | $112.0K |
| Total current liabilities | $4.6M | $2.2M | $3.3M | $9.5M | $16.5M | $7.0M | $2.8M | $437.9K | $156.2K |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M | $7.0M | $13.2M | $12.7M | $11.8M |
| Retained earnings | -$139.7M | -$129.5M | -$121.6M | -$110.9M | -$85.8M | -$56.0M | $2.5M | -$233.8K | -$5.2K |
| Total equity | $3.2M | $3.7M | -$651.3K | -$4.0M | -$8.2M | -$6.7M | -$6.7M | $5.0M | $5.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M | -$1.2M | -$1.4M | -$1.2M | — |
| Depreciation and amortisation | $6.5K | $0 | $0 | $0 | $151 | $201 | — | — | — |
| Stock-based compensation | $177.1K | $110.7K | $879.2K | $1.1M | $121.8K | $178.7K | — | — | — |
| Capital expenditure | $123.6K | — | — | — | — | — | — | — | — |
| Investing cash flow | -$123.6K | — | — | $4.5K | — | $183.4M | $11.9M | $838.6K | — |
| Financing cash flow | $8.7M | $9.9M | $8.8M | $8.8M | $20.3M | $1.1M | -$11.0M | -$32.0K | — |
| Buybacks | — | — | — | — | — | $184.8M | $11.6M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013633.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.9M | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | $2.1M | -$1.1M | -$160.9K | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |